SCHEMBL4122842

SCHEMBL4122842

CCCc1ccc(NC(=O)Nc2ccc(C(=O)OCC)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.69
MAPT P10636 6/20 0.69
MEN1 O00255 5/20 0.69
TRPV1 Q8NER1 2/20 0.69
CASP3 P42574 1/20 0.69
SENP7 Q9BQF6 1/20 0.69
NAMPT P43490 3/20 0.61
GAA P10253 2/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TSHR P16473 1/20 0.58
MAPK1 P28482 2/20 0.57
LMNA P02545 2/20 0.57
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118303 0.90 KMT2A (0.68) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4112088 0.89 KMT2A (0.75) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4122892 0.88 MAPT (0.64) KMT2AMAPTMEN1RAB9ANPC1
SCHEMBL571227 0.87 CA1 (0.63) KMT2AMEN1NAMPTL3MBTL1CA12
SCHEMBL4117463 0.87 MAPT (0.72) KMT2AMAPTMEN1TRPV1NAMPT
SCHEMBL4104395 0.87 KMT2A (0.71) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4920241 0.85 MAPT (0.73) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4113307 0.84 MAPT (0.77) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4920477 0.84 MAPT (0.68) KMT2AMAPTMEN1TRPV1CASP3
SCHEMBL4911071 0.84 KMT2A (0.68) KMT2AMAPTMEN1TRPV1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 KMT2A 2807/4885MAPT 1654/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.